TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Price Performance

TLSI stock opened at $5.67 on Tuesday. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $10.42. The company has a market cap of $172.90 million, a P/E ratio of -2.28 and a beta of 0.48. The stock’s fifty day moving average price is $5.34 and its 200-day moving average price is $4.72.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TLSI. Roth Mkm restated a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on shares of TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $11.56.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 4,826 shares of the company’s stock in a transaction on Monday, January 27th. The stock was acquired at an average cost of $5.42 per share, for a total transaction of $26,156.92. Following the purchase, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at $2,327,906.26. This trade represents a 1.14 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sean Murphy acquired 15,000 shares of the business’s stock in a transaction on Monday, January 27th. The shares were bought at an average cost of $5.31 per share, with a total value of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares in the company, valued at approximately $970,306.92. This represents a 8.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 54,856 shares of company stock valued at $294,608 over the last three months. Corporate insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.